Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant
            <i>Klebsiella pneumoniae</i>

Bao, Juan Francisco Gibaja; Wu, Nannan; Zeng, Yanwu; Chen, Liguang; Li, Linlin; Yang, Lan; Zhang, Yiyuan; Guo, Mingquan; Li, Lisha; Li, Jie; Tan, Demeng; Cheng, Mengjun; Gu, Jingmin; Qin, Jinghong; Liu, Jiazheng; Li, Shiru; Pan, Guang-Qiang; Jin, Xin; Yao, Bangxin; Guo, Xin; Zhu, Tongyu; Le, Shuai

doi:10.1080/22221751.2020.1747950

Cited by 120 publications

(96 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study describes the recovery of a patient with a recurrent UTI after the administration of five lytic phages and the antibiotics TMP/SMX. All K. pneumoniae strains isolated from the patient UTI were completely resistant to TMP/SMX [ 67 ].…”

Section: Phage Therapy In Combination With Antibioticsmentioning

confidence: 99%

Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

et al. 2020

View full text Add to dashboard Cite

Urinary tract infections represent a major public health problem as the rapid emergence of antibiotic-resistant strains among uropathogens is causing the failure of many current treatments. The use of bacteriophages (phages) and their derivatives to combat infectious diseases is an old approach that has been forgotten by the West for a long time, mostly due to the discovery and great success of antibiotics. In the present so-called “post-antibiotic era”, many researchers are turning their attention to the re-discovered phage therapy, as an effective alternative to antibiotics. Phage therapy includes the use of natural or engineered phages, as well as their purified lytic enzymes to destroy pathogenic strains. Many in vitro and in vivo studies have been conducted, and these have proved the great potential for this therapy against uropathogenic bacteria. Nevertheless, to date, the lack of appropriate clinical trials has hindered its widespread clinic application.

show abstract

Section: Phage Therapy In Combination With Antibioticsmentioning

confidence: 99%

Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Since then, phages have been employed clinically to treat bacterial infections as a natural antimicrobial [ 7 , 8 ]. Phage therapy has been proven to be efficacious in at least one modern efficacy (phase I/II) clinical trial [ 9 ], and there are some successful cases of applying phages to the treatment of human drug-resistant bacterial infections [ 10 , 11 , 12 , 13 , 14 ]. Bacteriophages provide an alternative useful antibacterial approach and have gradually been used in combination with standard antibiotics against the drug resistance of pathogenic bacteria, which is mainly based on the phage–antibiotic synergy (PAS) effect [ 15 ].…”

mentioning

confidence: 99%

Aminoglycoside Antibiotics Inhibit Mycobacteriophage Infection

et al. 2020

View full text Add to dashboard Cite

Antibiotic resistance is becoming the biggest threat to global health. At the same time, phage therapy is witnessing a return of interest. The therapeutic use of bacteriophages that infect and kill bacteria is a suitable strategy to combat antibiotic resistance. Furthermore, bacteriophages are increasingly used in combination with standard antibiotics against drug-resistant pathogens. Interestingly, we found that the engineered mycobacteriophage phAE159 and natural phage D29 cannot infect the Mycobacterium tuberculosis in the presence of kanamycin, hygromycin or streptomycin, but the phage infection was not affected in the presence of spectinomycin. Based on a series of studies and structural analysis of the above four aminoglycoside antibiotics, it could be speculated that the amino sugar group of aminoglycoside might selectively inhibit mycobacteriophage DNA replication. Our discovery that broad-spectrum antibiotics inhibit phage infection is of great value. This study will provide guidance for people to combine phage and antibiotics to treat M. tuberculosis.

show abstract

“…A phage susceptibility test is a method followed by bacterial diagnosis, to simultaneously test the contents of a sub-library (specific to the target bacterial species) of phage candidates against the bacteria isolated from a patient, thereby identifying phages for patient-specific precision therapy. Laboratory-developed phage susceptibility tests are widely used for therapeutic phage screening ( Aslam et al, 2019 ; Dedrick et al, 2019 ; Kuipers et al, 2019 ; Nir-Paz et al, 2019 ; Bao et al, 2020 ; Petrovic Fabijan et al, 2020 ). Additionally, given the specificity of phage-host interactions, the distinguished phage susceptibility profiles can enable rapid fingerprinting of bacterial substrains.…”

Section: Constructing a Nosocomial Infection Monitoring Database By Umentioning

confidence: 99%

Potential of Therapeutic Bacteriophages in Nosocomial Infection Management

Zhu

2021

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

Nosocomial infections (NIs) are hospital-acquired infections which pose a high healthcare burden worldwide. The impact of NIs is further aggravated by the global spread of antimicrobial resistance (AMR). Conventional treatment and disinfection agents are often insufficient to catch up with the increasing AMR and tolerance of the pathogenic bacteria. This has resulted in a need for alternative approaches and raised new interest in therapeutic bacteriophages (phages). In contrast to the limited clinical options available against AMR bacteria, the extreme abundance and biodiversity of phages in nature provides an opportunity to establish an ever-expanding phage library that collectively provides sustained broad-spectrum and poly microbial coverage. Given the specificity of phage-host interactions, phage susceptibility testing can serve as a rapid and cost-effective method for bacterial subtyping. The library can also provide a database for routine monitoring of nosocomial infections as a prelude to preparing ready-to-use phages for patient treatment and environmental sterilization. Despite the remaining obstacles for clinical application of phages, the establishment of phage libraries, pre-stocked phage vials prepared to good manufacturing practice (GMP) standards, and pre-optimized phage screening technology will facilitate efforts to make phages available as modern medicine. This may provide the breakthrough needed to demonstrate the great potential in nosocomial infection management.

show abstract

Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae

Abstract: Le (2020) Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiellapneumoniae,

Cited by 120 publications

References 15 publications

Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

Aminoglycoside Antibiotics Inhibit Mycobacteriophage Infection

Potential of Therapeutic Bacteriophages in Nosocomial Infection Management

Contact Info

Product

Resources

About